bendamustine / Generic mfg.  >>  Phase 2
Welcome,         Profile    Billing    Logout  

38 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
bendamustine / Generic mfg.
2011-000796-14: COSMIC: Chemotherapy plus Ofatumumab at Standard or Mega dose In CLL

Ongoing
2
82
Europe
Ofatumumab, Fludarabine, Cyclophosphamide, Cyclophosphamide Injection, Bendamustine, Concentrate for solution for infusion, Film-coated tablet, Solution for infusion, Coated tablet, Powder for solution for injection, Powder for concentrate for solution for infusion, Arzerra (Ofatumumab), Cyclophosphamide Injection
Leeds Teaching Hospitals NHS Trust, GlaxoSmithKline
Chronic Lymphocytic Leukaemia (CLL), Leukaemia is a cancer of the white blood cells. CLL is the most common type of Leukaemia. People with CLL make too many white blood cells called lymphocytes., Diseases [C] - Cancer [C04]
 
 
2012-005338-13: Treatment with Ofatumumab and Bendamustine in patients with lymphoma resistant to previous therapies Trattamento con Ofatumumab e Bendamustina in pazienti con linfoma resistente alle precedenti terapie

Ongoing
2
73
Europe
Bendamustine, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Arzerra
Istituto Clinico Humanitas - Humanitas Cancer Center, Regione Lombardia, GlaxoSmithKline
Non-Hodgkin's Follicular and Non-Follicular indolent lymphomas, relapsed/refractory Linfomi non Hodgkin indolenti follicolari e non follicolari, recidivati/refrattari, Indolent Lymphoma Linfomi indolenti, Diseases [C] - Cancer [C04]
 
 
2014-000130-37: Clinical trial to evaluate the efficacy and the safety of a combination of bendamustine-melphalan as preparative regimen to autologous transplantation of hematopoietic cells for multiple myeloma who did not responded after previous high-dose therapy STUDIO CLINICO PER VALUTARE L'EFFICACIA E LA SICUREZZA DELL'ASSOCIAZIONE DI BENDAMUSTINA-MELFALAN COME REGIME PREPARATORIO AL TRAPIANTO AUTOLOGO DI CELLULE EMATOPOIETICHE IN PAZIENTI AFFETTI DA MIELOMA MULTIPLO CHE NON HANNO RISPOSTO A PRECEDENTI TERAPIE AD ALTE DOSI.

Ongoing
2
73
Europe
Levact ® i.v., Not applicable, Powder and solution for solution for injection, Levact®
FONDAZIONE NEOPLASIE SANGUE ONLUS (FO.NE.SA. Onlus), Mundipharma
Multiple myeloma Mieloma multiplo, Patients with multiple myeloma Pazienti con mieloma multiplo, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT02401503 / 2014-000580-40: Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG)

Checkmark In combination with obinutuzumab following bendamustine
Aug 2018 - Aug 2018: In combination with obinutuzumab following bendamustine
Active, not recruiting
2
66
Europe
Bendamustine, GA101, Obinutuzumab, ABT-199, Venetoclax, GDC-0199
German CLL Study Group, Hoffmann-La Roche, AbbVie
Chronic Lymphocytic Leucemia
12/16
12/24
2017-004628-31: Venetoclax after chemotherapy R-BAC in high-risk elderly patients with mantle cell lymphoma Venetoclax dopo chemioterapia R-BAC in pazienti anziani affetti da linfoma mantellare

Not yet recruiting
2
130
Europe
Venclyxto, Film-coated tablet, Venclyxto
Fondazione Italiana Linfomi ONLUS, AbbVie S.r.l.
Mantle Cell Lymphoma in elderly patients Linfoma mantellare in pazienti anziani, Mantle Cell Lymphoma in elderly patients Linfoma mantellare in pazienti anziani, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT03623373: Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma

Active, not recruiting
2
13
US
Bendamustine, Treanda, Bendeka, Rituximab, Rituxan, Rituxan Hycela, Acalabrutinib, Calquence®, Cytarabine, Cytosar-U, Leukapheresis, Peripheral blood, Oral rinse, Bone marrow collection
Washington University School of Medicine, Acerta Pharma BV
Mantle Cell Lymphoma
02/20
02/25
2012-003947-31: OPTIMAL: Optimising Renal Outcome in Myeloma renal failure

Not yet recruiting
2
120
Europe
Thalidomide celgene, Velcade, Levact, J9041, Capsule, hard, Injection, Infusion, Thalidomide Celgene™, Velcade, Levact
Oxford University Hospitals NHS Trust, Janssen-Cilag, NAPP Pharmaceuticals
Myeloma and renal impairment, Cancer of bone marrow, kidney disfunction, Diseases [C] - Cancer [C04]
 
 
2018-003270-27: Evaluation of a treatment with bendamustine, followed by obinutuzumab,zanubrutinib and venetoclax in patients with relapsed chronic lymphocyticleukemia

Not yet recruiting
2
40
Europe
Bendamustine, Obinutuzumab / GA101, ABT-199 (GDC-0199), Venetoclax, Zanubrutinib, RO5072759, BGB-3111, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Tablet, Capsule, hard, Gazyvaro, Venclyxto (Venetoclax)
Universität zu Köln B.1.2, BeiGene Ltd., Roche Pharma AG
Patients with relapsed/refractory CLL requiring treatment, Patients with relapsed chronic lymphocytic leukaemia in need oftreatment, Diseases [C] - Cancer [C04]
 
 
PrE0403, NCT03113422: Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy

Completed
2
56
US
Induction Venetoclax, GDC-0199, ABT-199, RO5537382, Maintenance Venetoclax
PrECOG, LLC., Genentech, Inc.
Follicular Lymphoma, Non-Hodgkin's Lymphoma Follicular, Non-Hodgkin's Lymphoma, Adult High Grade
05/21
01/23
FIL_V-RBAC, NCT03567876: Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL

Active, not recruiting
2
141
Europe
Venetoclax, Venclyxto (commercial name)
Fondazione Italiana Linfomi - ETS, AbbVie
Lymphoma, Mantle-Cell
07/21
07/25
GABe2016, NCT03492775 / 2016-000755-27: First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 Years

Completed
2
46
Europe
Obinutuzumab, GA 101, Bendamustine, Bendamustine hydrochloride; Ribomustin
Prof. Dr. Wolfgang Hiddemann, Hoffmann-La Roche, Mundipharma Research GmbH & Co KG
Indolent Non-hodgkin Lymphoma
11/21
12/22
CLL2-BCG, NCT02445131 / 2014-000582-47: Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL

Completed
2
48
Europe
Bendamustine, GA101, Obinutuzumab, CAL-101, Idelalisib
German CLL Study Group, Hoffmann-La Roche, Gilead Sciences
Chronic Lymphocytic Leucemia
03/22
03/22
PrE0405, NCT03834688: Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age

Active, not recruiting
2
33
US
Venetoclax, GDC-0199, ABT-199, RO5537382, Bendamustine, Bendamustine hydrochloride, Rituximab, Chimeric anti-CD20 monoclonal antibody, Rituxan
PrECOG, LLC., Genentech, Inc.
Mantle Cell Lymphoma
10/22
11/24
2020-002935-30: Venetoclax in combination with Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients with Mantle Cell Lymphoma. Venetoclax in Kombination mit Ibrutinib und Rituximab oder konventionelle Chemotherapie (Bendamustin) und Ibrutinib und Rituximab bei Patienten mit Mantelzell-Lymphoms.

Not yet recruiting
2
150
Europe
Film-coated tablet, IMBRUVICA®140 mg Filmtabletten, Venclyxto® 10 mg Filmtabletten, Venclyxto® 50 mg Filmtabletten, Venclyxto® 100 mg Filmtabletten
University Medical Center of the Johannes Gutenberg-University Mainz, AbbVie Inc., Janssen Pharmaceutica NV
Mantle Cell Lymphoma Mantelzell-Lymphom, malignant lymph node disease bösartige Lymphknotenerkrankung, Diseases [C] - Cancer [C04]
 
 
SGN35-015, NCT01716806 / 2019-003982-17: A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

Checkmark Additional data for front-line Hodgkin's lymphoma in elderly patients (ASH 2014)
Nov 2014 - Nov 2014: Additional data for front-line Hodgkin's lymphoma in elderly patients (ASH 2014)
Checkmark For newly diagnosed Hodgkin's lymphoma in elderly patients
Dec 2013 - Dec 2013: For newly diagnosed Hodgkin's lymphoma in elderly patients
Checkmark Elderly chemo-intolerant Hodgkin's lymphoma patients
More
Completed
2
131
Canada, US
brentuximab vedotin, Adcetris; SGN-35, bendamustine, dacarbazine, nivolumab
Seagen Inc., Bristol-Myers Squibb
Hodgkin Disease, Peripheral T Cell Lymphoma
04/23
09/23
NCT03311126: Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma

Terminated
2
21
US
Bendamustine, Obinutuzumab, GA101, RO5072759
University of Wisconsin, Madison, Genentech, Inc.
Mantle Cell Lymphoma, Non-hodgkin Lymphoma, Non Hodgkin Lymphoma
07/23
07/23
NCT03872180: Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

Active, not recruiting
2
23
US
Bendamustine, SDX-105, Obinutuzumab, GA-101, Gazyva, RO5072759, Venetoclax, ABT-199, GDC-0199, RG7601, Venclexta, RO5537382
Emory University, Genentech, Inc., National Cancer Institute (NCI), National Institutes of Health (NIH)
CCND1 Positive, Mantle Cell Lymphoma, t(11;14) Positive
09/24
04/26
NCT01437709: Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant

Completed
2
30
US
Ofatumumab (This arm is closed), Ofatumumab + Bendamustine
Memorial Sloan Kettering Cancer Center, GlaxoSmithKline
Mantle Cell Lymphoma
09/23
09/23
NCT04587687: Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

Recruiting
2
23
US
Bendamustine Hydrochloride, Bendamustin Hydrochloride, Bendeka, Cytostasan Hydrochloride, Levact, Ribomustin, SyB L-0501, Treanda, Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35
Joseph Tuscano, National Cancer Institute (NCI), Seagen Inc.
Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
12/24
05/25
DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Recruiting
2
168
Europe, RoW
MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab
Miltenyi Biomedicine GmbH, ICON plc
Diffuse Large B-cell Lymphoma
12/24
07/27
CheckMate 744, NCT02927769 / 2016-002347-41: A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

Hourglass Feb 2021 - Dec 2021 : From CheckMate 744 trial for r/r classic hodgkin lymphoma
Checkmark FRom CheckMate 744 trial at ASH 2018 [screenshot]
Dec 2018 - Dec 2018: FRom CheckMate 744 trial at ASH 2018 [screenshot]
Active, not recruiting
2
72
Europe, Canada, US, RoW
Nivolumab, BMS-936558, Opdivo, brentuximab vedotin, bendamustine
Bristol-Myers Squibb, Seagen Inc.
Hodgkin Disease
06/24
11/24
GOLSEEK-2, NCT06425302: A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

Not yet recruiting
2
90
Europe, Canada, US, RoW
Golcadomide, CC-99282, BMS-986369, Rituximab, Mabthera, Cyclophosphamide, Endoxan, Doxorubicin, Caelyx, pegylated liposomal doxorubicin, PLD, Vincristine, Prednisone, Bendamustine
Celgene
Lymphoma, Follicular
11/26
11/28
BRAWM, NCT04624906: Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia

Active, not recruiting
2
59
Canada
Acalabrutinib, Calquence, Bendamustine, Treanda, Rituximab, Rituxan
Sunnybrook Health Sciences Centre, AstraZeneca
Waldenstrom Macroglobulinemia
12/24
03/30
DALY II USA, NCT04792489: / MB-CART2019.1 for DLBCL

Recruiting
2
110
US
zamtocabtagene autoleucel (MB-CART2019.1), Cyclophosphamide, Fludarabine, Bendamustine
Miltenyi Biomedicine GmbH
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma (HGBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), Transformed Lymphoma, Central Nervous System Lymphoma
12/24
12/26
NCT05025423: Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma

Recruiting
2
40
US
Venetoclax Oral Tablet [Venclexta], rituximab infusion [Rituxan], Bendamustine infusion
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, AbbVie
Mantle Cell Lymphoma
09/25
09/26
NCT03755804: Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

Recruiting
2
250
US
bendamustine, TREANDA (R), Etoposide, VP-16, Vepeside, Doxorubicin, Adriamycin (R), Bleomycin, Blenoxane (R), Vincristine, Oncovin (R), Vinblastine, Velban (R), Prednisone, Prednisolone, Filgrastim, Neupogen (R), Brentuximab Vedotin, Adcetris, Cyclophosphamide, Cytoxan (R), DTIC, DACARBAZINE (R), Dimethyl Triazeno Imidazole Carboximide, Quality of Life Measurements, Quality of Life Measurements (QOL), Radiotherapy, radiation therapy, irradiation
St. Jude Children's Research Hospital, Teva Pharmaceuticals USA, Seagen Inc.
Hodgkin Lymphoma
01/27
07/28
REFRACT, NCT05848765: Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

Recruiting
2
284
Europe
Epcoritamab, Lenalidomide, Rituximab, Obinutuzumab, Bendamustine, Vincristine, Doxorubicin, Cyclophosphamide, Prednisone, Investigation agent 2, Investigation agent 3
University of Birmingham, Cancer Research UK, Genmab
Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma
05/29
11/31
NCT01754402: Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma

Active, not recruiting
1/2
56
US
Bendamustine, Treanda, Bendeka, Pomalidomide, CC-4047, Pomalyst, Dexamethasone
Cristina Gasparetto, Celgene
Multiple Myeloma
12/16
01/25
ZUMA-1, NCT02348216 / 2015-005007-86: Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

Checkmark Data from ZUMA-1 trial for R/R LBCL at ASH 2022
Dec 2022 - Dec 2022: Data from ZUMA-1 trial for R/R LBCL at ASH 2022
Checkmark Presentation from ZUMA-1 trial for DLBCL at ASTCT 2021
Feb 2021 - Feb 2021: Presentation from ZUMA-1 trial for DLBCL at ASTCT 2021
Checkmark Presentation from ZUMA-1 trial for DLBCL at ASH 2020
More
Completed
1/2
307
Europe, Canada, US, RoW
Axicabtagene Ciloleucel, Yescarta®, Fludarabine, Cyclophosphamide, Levetiracetam, Tocilizumab, Dexamethasone, High-dose methylprednisolone, Bendamustine, Rituximab, Doxorubicin, Prednisone, Vincristine, Ifosfamide, Carboplatin, Etoposide, Gemcitabine, Oxaliplatin, Cisplatin, Methylprednisolone
Kite, A Gilead Company
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL), High Grade B-cell Lymphoma (HGBCL)
07/23
07/23
2020-002927-13: Atezolizumab treatment together with the BEGEV regimen in patients with resistant Hodgkin's lymphoma and candidates for autologous stem cell transplantation. Trattamento di atezolizumab associato a combinazione BEGEV in pazienti con linfoma di Hodgkin resistente e candidati al trapianto autologo di cellule staminali.

Not yet recruiting
1/2
140
Europe
Atezolizumab, Bendamustina, Gemcitabina, Vinorelbina, [IMP2], [IMP3], [IMP4], [IMP5], [IMP6], [IMP1], Concentrate for solution for infusion, Powder for concentrate for solution for infusion, TECENTRIQ - 840 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 20 ML (60 MG/ML) - 1 FLACONCINO, BENDAMUSTINA ACCORD - 2,5 MG/ML POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - 5 FLACONCINI DA 40 ML, BENDAMUSTINA ACCORD - 2,5 MG/ML POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - 5 FLACONCINI DA 10 ML, Gemcitabina cloridrato, VINORELBINA ACTAVIS - 10 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO DI VETRO DA 5 ML, TECENTRIQ - 1200 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 20 ML (60 MG/ML) - 1 FLACONCINO
FONDAZIONE ITALIANA LINFOMI ONLUS, Roche S.p.A.
Refractory/relapsed Hodgkin Lymphoma. Linfoma di Hodgkin ricaduto/refrattario., Refractory/relapsed Hodgkin Lymphoma. Linfoma di Hodgkin ricaduto/refrattario., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2022-001040-23: Treatment of relapsed or refractory B-cell lymphoma with CAR-T therapy produced by a new technology. Tratamiento del linfoma de células B en recaída o refractario con terapia CAR-T producida por una nueva tecnología.

Not yet recruiting
1/2
27
Europe
TranspoCART19, Cyclophosphamide, Fludarabina, Bendamustina, Tocilizumab, Cetuximab, Injection/infusion, Powder for solution for injection/infusion, Concentrate for solution for injection/infusion, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, , Genoxal 25mg/ml, Fludarabina Teva 25 mg/ml, Bendamustina Tillomed 2,5 mg/ml, RoActemra 20 mg/m, Erbitux 5 mg/ml
Instituto de Investigación Biomédica de Salamanca (IBSAL) - IECSCYL, Instituto de Salud Carlos III
Relapsed or refractory B-cell lymphoma Linfoma de células B en recaída o refractario, Relapsed or refractory B-cell lymphoma Linfoma de células B en recaída o refractario, Diseases [C] - Cancer [C04]
 
 
NCT03739619: Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Active, not recruiting
1/2
54
US
Bendamustine, Bendamustine Hydrochloride, Cytostasan Hydrochloride, Levact, Ribomustin, SyB L-0501, Treanda, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
Emory University, Bristol-Myers Squibb, National Cancer Institute (NCI), National Institutes of Health (NIH)
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Hodgkin Lymphoma
12/24
12/24
NCT05551936: A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma

Recruiting
1/2
42
US
Bendamustine, Bendeka, Treanda, Rituximab, Rituxan, Tazemetostat, Tazverik
Vaishalee Kenkre, Epizyme, Inc., University of Wisconsin, Madison
Follicular Lymphoma
08/24
05/25
NCT03997968: A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Active, not recruiting
1/2
170
US
CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine, CYT-0851 in combination with rituximab and bendamustine
Cyteir Therapeutics, Inc.
Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
07/24
12/24
NCT04673617: AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Recruiting
1/2
108
US
AB-101, Rituximab, Interleukin-2, Cyclophosphamide, Fludarabine, Bendamustine
Artiva Biotherapeutics, Inc.
Non Hodgkin Lymphoma
11/24
11/24
FIL_A-BEGEV, NCT05300282: Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients

Recruiting
1/2
140
Europe
Atezolizumab, BEGEV, Bendamustine, Gemcitabine, Vinorelbine
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Relapsed or Refractory Hodgkin's Lymphoma
05/25
12/28
NCT05451771: Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Recruiting
1/2
53
US
Venetoclax Oral Tablet, 200 mg, Venclexta, FISH assay, t(11;14) FISH assay, Venetoclax Oral Tablet, 400 mg, Dexamethasone Oral, 10 mg, Decadron, Hemady, Dexamethasone Oral, 20 mg, Daratumumab Injection, Darzalex, Bendamustine, Treanda, Pomalidomide, Pomalyst, Ixazomib, Ninlaro, Venetoclax MTD with Dexamethasone
Rajshekhar Chakraborty, MD, Genentech, Inc.
AL Amyloidosis
09/26
09/26
EPCORE NHL-2, NCT04663347 / 2020-000845-15: Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

Checkmark Data from arm 6 of EPCORE NHL-2 trial for r/r/ follicular lymphoma at ASH 2022
Dec 2022 - Dec 2022: Data from arm 6 of EPCORE NHL-2 trial for r/r/ follicular lymphoma at ASH 2022
Checkmark Data from arm 2b of EPCORE NHL-2 trial for r/r follicular lymphoma at ASH 2022
Dec 2022 - Dec 2022: Data from arm 2b of EPCORE NHL-2 trial for r/r follicular lymphoma at ASH 2022
Checkmark Data from arm-4 of EPCORE NHL-2 trial for r/r DLBCL at ASH 2022
More
Recruiting
1/2
662
Europe, US, RoW
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, R-CHOP, rituximab and lenalidomide, R2, rituximab and bendamustine, BR, rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin, R-DHAX/C, gemcitabine and oxaliplatin, GemOx, Epcoritamab, GEN3013, DuoBody®-CD3xCD20, EPKINLY™, rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone, R mini-CHOP, Lenalidomide, rituximab, ifosfamide, carboplatin, and etoposide phosphate, R-ICE
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
03/29
03/29

Download Options